Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension

EuroIntervention

Volumn 11, Issue 1, 2015, Pages 110-116

  Ott, Christian ^a   Schmid, Axel ^a   Toennes, Stefan W ^b   Ditting, Tilmann ^a   Veelken, Roland ^a   Uder, Michael ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Central pulse pressure; Predictor; Renal denervation; Treatment resistant hypertension

Indexed keywords

ABLATION CATHETER; ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CENTRAL PULSE PRESSURE; FEMALE; HUMAN; KIDNEY DENERVATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PULSE PRESSURE; PULSE WAVE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; AGED; AUTONOMIC DENERVATION; BLOOD PRESSURE; CATHETER ABLATION; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DEVICES; DRUG EFFECTS; DRUG RESISTANCE; ELECTRODE; EQUIPMENT DESIGN; GERMANY; HYPERTENSION; INNERVATION; KIDNEY; KIDNEY ARTERY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ANTIHYPERTENSIVE AGENT;

AGED; ANTIHYPERTENSIVE AGENTS; AUTONOMIC DENERVATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE; ELECTRODES; EQUIPMENT DESIGN; FEMALE; GERMANY; HUMANS; HYPERTENSION; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULSE WAVE ANALYSIS; RENAL ARTERY; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84930152491     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV11I1A19     Document Type: Article

References (48)

1. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension. 2009;54:388-92.
2. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.
3. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-30.
4. Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens. 2011;29:454-9.
5. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-25.
6. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-9.
7. Williams B. Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity - mortality. J Hypertens. 2012;30:S13-8.
8. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
9. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
10. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Bohm M, Schmieder RE. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880-6.
11. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659-82.
12. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245:F1-14.
13. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-90.
14. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, Severino F, Rosa J, Adiyaman A, Fadl Elmula FE, Taylor A, Pechere-Bertschi A, Wuerzner G, Jokhaji F, Kahan T, Renkin J, Monge M, Widimsky P, Jacobs L, Burnier M, Mark PB, Kjeldsen SE, Andersson B, Sapoval M, Staessen JA; European Network COordinating research on Renal Denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-6.
15. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-40.
16. Wilder J. Basimetric approach (law of initial value) to biological rhythms. Ann N Y Acad Sci. 1962;98:1211-20.
17. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
18. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-41.
19. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Böhm M; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-57.
20. Ott C, Haetinger S, Schneider MP, Pauschinger M, Schmieder RE. Comparison of two noninvasive devices for measurement of central systolic blood pressure with invasive measurement during cardiac catheterization. J Clin Hypertens. 2012;14:575-9.
21. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38:932-7.
22. Smulyan H, Siddiqui DS, Carlson RJ, London GM, Safar ME. Clinical utility of aortic pulses and pressures calculated from applanated radial-artery pulses. Hypertension. 2003;42:150-5.
23. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-74.
24. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
25. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-24.
26. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, Bauer A. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013;62:2124-30.
27. Dorr O, Liebetrau C, Mollmann H, Gaede L, Troidl C, Rixe J, Hamm C, Nef H. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014;63:984-90.
28. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001;87:805-7, A9.
29. Schlaich M. Biomarkers for the prediction of blood pressure response to renal denervation: a long way to go. Hypertension. 2014;63:907-8.
30. Pickering TG. Arterial stiffness as a cause of resistant hypertension? J Clin Hypertens (Greenwich). 2007;9:390-5.
31. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43:1239-45.
32. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension. 2005;45:1050-5.
33. Safar ME, Temmar M, Kakou A, Lacolley P, Thornton SN. Sodium intake and vascular stiffness in hypertension. Hypertension. 2009;54:203-9.
34. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43:1388-95.
35. O'Rourke M. Mechanical principles in arterial disease. Hypertension. 1995;26:2-9.
36. Izzo JL Jr. Arterial stiffness and the systolic hypertension syndrome. Curr Opin Cardiol. 2004;19:341-52.
37. O'Rourke MF, Hayward CS. The pulse of cardiology: quo vadis? J Am Coll Cardiol. 2009;54:714-7.
38. Laurent S, Alivon M, Beaussier H, Boutouyrie P. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann Med. 2012;44:S93-7.
39. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, Wagenpfeil S, Schmieder RE, Bohm M, Mahfoud F. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65:193-9.
40. Laurent S, Juillerat L, London GM, Nussberger J, Brunner H, Safar ME. Increased response of brachial artery diameter to norepinephrine in hypertensive patients. Am J Physiol. 1988;255:H36-43.
41. Boutouyrie P, Lacolley P, Girerd X, Beck L, Safar M, Laurent S. Sympathetic activation decreases medium-sized arterial compliance in humans. Am J Physiol. 1994;267:H1368-76.
42. Failla M, Grappiolo A, Carugo S, Calchera I, Giannattasio C, Mancia G. Effects of cigarette smoking on carotid and radial artery distensibility. J Hypertens. 1997;15:1659-64.
43. Failla M, Grappiolo A, Emanuelli G, Vitale G, Fraschini N, Bigoni M, Grieco N, Denti M, Giannattasio C, Mancia G. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens. 1999;17:1117-23.
44. Angouras DC, Dosios TJ, Dimitriou CA, Chamogeorgakis TP, Rokkas CK, Manos TA, Sokolis DP. Surgical thoracic sympathectomy induces structural and biomechanical remodeling of the thoracic aorta in a porcine model. J Surg Res. 2012;172:68-76.
45. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR; ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753-60.
46. Vergnaud AC, Protogerou AD, Blacher J, Safar ME. From 'optimal' to 'borderline' blood pressure in subjects under chronic antihypertensive therapy. J Hypertens. 2008;26:138-44.
47. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401.
48. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension. N Engl J Med. 2014;371:184.